Pharma BD Deal Intelligence
A $4.6B bet on a hybrid innovator-generics model that collapsed when concealed FDA manufacturing fraud at Ranbaxy's plants surfaced, forcing a $3.9B writedown and a $500M fine. Daiichi Sankyo exited via distressed sale of Ranbaxy to Sun Pharma for $4B, wiping out nearly the entire acquisition value.
Worst pharma deal of the decade: concealed FDA fraud destroyed $3.9B in value
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Daiichi Sankyo acquired a controlling 63.9% stake in Ranbaxy Laboratories for approximately $4.6 billion, seeking to build a hybrid innovator-generics model and gain access to fast-growing emerging markets, particularly India. The deal later proved problematic due to FDA compliance issues at Ranbaxy facilities.
Daiichi Sankyo Company, Limited closes acquisition/merger of Ranbaxy Laboratories Limited for $4.6B, establishing strategic position and initiating integration.
Daiichi Sankyo $4.6B Ranbaxy acquisition devastated by concealed FDA fraud $3.9B writedown $500M fine and distressed sale to Sun Pharma for $4B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited (this deal) | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Ambit Biosciences | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Zepharma Inc. | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Plexxikon Inc. | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
← Browse all deals · How we score deals
More: 2008 deals · Daiichi Sankyo Company, Limited deals · Cardiovascular deals